Search research articles
Contact Us
Filters
Showing results (231-240 of 241) with videos related to
Page
of 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Daniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)
|
January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
International Journal of Cancer
|
July 14, 2022
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
Cécile Torregrosa, Simon Pernot, Pauline Vaflard, et al.
The Oncologist
|
June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Camille Evrard, Antoine Pelras, Simon Rivet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade, et al.
JAMA Surgery
|
September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Robert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
European Journal of Human Genetics : EJHG
|
August 10, 2018
Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations
Pascal Pujol, Pierre Vande Perre, Laurence Faivre, et al.
Nature
|
May 7, 2025
Activation of lysosomal iron triggers ferroptosis in cancer
Tatiana Cañeque, Leeroy Baron, Sebastian Müller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2021
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
Pascal Pujol, Massimo Barberis, Philp Beer, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 241) with videos related to
Sort By:
Page
of 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Daniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)
|
January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
International Journal of Cancer
|
July 14, 2022
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
Cécile Torregrosa, Simon Pernot, Pauline Vaflard, et al.
The Oncologist
|
June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Camille Evrard, Antoine Pelras, Simon Rivet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade, et al.
JAMA Surgery
|
September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Robert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
European Journal of Human Genetics : EJHG
|
August 10, 2018
Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations
Pascal Pujol, Pierre Vande Perre, Laurence Faivre, et al.
Nature
|
May 7, 2025
Activation of lysosomal iron triggers ferroptosis in cancer
Tatiana Cañeque, Leeroy Baron, Sebastian Müller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2021
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
Pascal Pujol, Massimo Barberis, Philp Beer, et al.
Page
of 25